Jounce Therapeutics Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Jounce Therapeutics (JNCE) PT Lowered to $15 at Baird
August 9, 2018 11:11 AM EDTBaird lowered its price target on Jounce Therapeutics (NASDAQ: JNCE) to $15.00 (from $20.00) while maintaining an Outperform rating following results.
Analyst Michael Ulz said the most notable update was the addition of two combination cohorts (ipiliumamb and pembrolizumab) to the ICONIC study, while the... More
Jounce Therapeutics (JNCE) Reports Q2 Loss of $0.14/Share
August 9, 2018 6:36 AM EDTJounce Therapeutics (NASDAQ: JNCE) reported Q2 EPS of ($0.14), versus ($0.11) reported last year. Revenue for the quarter came in at $19.38 million versus the consensus estimate of $12.91 million.
For earnings history and earnings-related data on Jounce Therapeutics (JNCE) click here.
... More